NEW YORK (GenomeWeb News) – Clinical Data today said that it has started a collaboration with the University of Pittsburgh to discover and validate genetic variants that could predict response to certain cancer treatments.

The partners will focus on variants in the Fc gamma receptor genes, which they believe could potentially predict patient response to monoclonal antibody therapies, such as cetuximab (Erbitux) and trastuzumab (Herceptin), and other monoclonal antibodies of the IgG1 subclass for treating cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.